Cargando…
Review of thalidomide in the treatment of newly diagnosed multiple myeloma
The role of thalidomide has been well established in the setting of relapsed or refractory multiple myeloma (MM). More recently, studies have been focused on upfront induction therapy. In newly diagnosed MM patients, thalidomide improved the response rates and the event-free survival induced by both...
Autores principales: | Cavallo, Federica, Boccadoro, Mario, Palumbo, Antonio |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374936/ https://www.ncbi.nlm.nih.gov/pubmed/18472975 |
Ejemplares similares
-
Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients
por: Wu, Shenghao, et al.
Publicado: (2015) -
The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
por: Bonello, Francesca, et al.
Publicado: (2020) -
Thalidomide and its analogues in the treatment of Multiple Myeloma
por: Latif, Tahir, et al.
Publicado: (2012) -
Higher single dose of bortezomib plus thalidomide and dexamethasone is a promising therapy for newly diagnosed multiple myeloma
por: Xu, Peipei, et al.
Publicado: (2019) -
A Combination of Melphalan, Prednisone, and 50 mg Thalidomide Treatment in Non-Transplant-Candidate Patients with Newly Diagnosed Multiple Myeloma
por: Chang, Hye Jung, et al.
Publicado: (2011)